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ABSTRACT In Argentina, new drugs can be authorized by presenting the drug’s cer-
tificate of approval in at least one of 15 countries considered to have rigorous health 
surveillance, without needing to carry out a local evaluation of the efficacy, safety or 
added therapeutic value of the new product. In this article, we evaluate the new drugs 
commercialized in Argentina in 2016 using different approaches: their approval by other 
regulatory agencies, the demonstration of their efficacy in randomized clinical trials, 
types of outcomes studied, rating of their added therapeutic value using two widely 
recognized scales, and their sale price to the public. It is concluded that, as a reflection 
of what occurs in developed countries, new drugs enter the market at exorbitant prices, 
but the majority do not represent a significant therapeutic advancements. The result is in-
creased risks to patients and an overburdening of the public and private funding systems.
KEY WORDS Drug Approval; Drug Evaluation; Drug Costs; Argentina.
RESUMEN En Argentina, los nuevos medicamentos pueden ser autorizados presentando 
el certificado de aprobación en al menos uno de los 15 países considerados de alta 
vigilancia sanitaria, sin necesidad de realizar una evaluación propia de eficacia, seguridad 
o valor terapéutico agregado por el nuevo producto. En este artículo, evaluamos los 
nuevos medicamentos comercializados en Argentina en el año 2016, utilizando 
diferentes enfoques: su aprobación por otras agencias reguladoras, demostración de 
eficacia en ensayos clínicos aleatorizados, tipo de desenlaces estudiados, calificación del 
valor terapéutico agregado por medio de dos escalas reconocidas y el precio de venta al 
público. Se concluye que, como reflejo de lo que ocurre en los países desarrollados, los 
nuevos medicamentos ingresan con precios exorbitantes, pero la mayoría no representa 
un avance terapéutico significativo. El resultado es un aumento de riesgos para los 
pacientes y una sobrecarga para los sistemas de financiación públicos y privados.
PALABRAS CLAVES Aprobación de Drogas; Evaluación de Medicamentos; Costos de los 
Medicamentos; Argentina.
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INTRODUCTION
Every year, a huge number of new pharma-
ceutical products are incorporated into the 
market, including new formulations, new 
combinations or new active ingredients. A 
general belief exists, even among health pro-
fessionals, that all new drugs offer therapeu-
tic innovation and better results in health, 
and therefore strategies that accelerate and 
optimize patient access to these drugs are 
desirable.
The evaluation process of regulatory 
agencies generally centers on each individ-
ual drug, the efficacy and safety of which 
must be proven in phase III controlled clin-
ical trials, often in comparison with a pla-
cebo. In this way, when a drug enters into 
the market, we know little about it in com-
parison with already existing products.
From a public health perspective, the 
value of a new drug lies in the therapeutic 
gain and the benefits to health for patients 
and for society as a whole. Diverse studies 
that have evaluated the clinical relevance of 
new drugs that have entered the market all 
show that the large majority do not offer any 
additional therapeutic benefit. According 
to the health authority of Canada, only 6% 
of the 1,147 new drugs approved between 
1990 and 2003 offered substantial therapeu-
tic advantage.(1) Additionally, an evaluation 
by the National Institute for Health Care 
Management in the US concluded that just 
under 15% of the 1,035 drugs approved by 
the Food and Drug Administration (FDA) 
between 1989 and 2000 were considered 
truly innovative.(2) Analyzing the pharma-
ceuticals introduced in Brazil between 2003 
and 2013, it was found that only 17.6% 
represented an “important therapeutic inno-
vation.”(3) The reviews from 2007 to 2016 
of the journal Prescrire regarding 992 new 
pharmaceuticals or new uses classified only 
23.3% (n=231) in one of the four catego-
ries describing some sort of benefit.(4)Ward 
et al., using a broader take on pharmaceuti-
cal innovation, found that of the 290 drugs 
incorporated in the 2001-2012 period in 
the British National Formulary, only 26% 
were very innovative and 19% moderately 
innovative.(5) In Australia, 32% (n=19) of the 
59 new drugs approved between 2005 and 
2007 were evaluated as having added thera-
peutic value.(6) Analyzing 122 new drugs au-
thorized by the European Medicines Agency 
(EMA) between 1999 and 2005, van Lujin et 
al. found that only 10% (n=13) were better 
than the existing drugs in terms of their ef-
fect on clinical endpoints.(7)
A good portion of these presumably 
new drugs are, in fact, reformulations of oth-
ers whose patent is about to expire, or mole-
cules similar to others in use that contribute 
little or nothing in comparison to the exist-
ing alternatives, reason for which they have 
come to be called “me too” drugs. 
In Argentina, new drugs – that is, drugs 
that were never commercialized in the 
country – can be approved in two ways, 
according to Decree 150/1992.(8) The first, 
and most frequent, is if the drugs have al-
ready been commercialized in at least one 
of the 15 countries with high-level health 
surveillance listed in Annex 1 of the Decree 
(Germany, Austria, Belgium, Canada, Hel-
vetic Republic, Denmark, Spain, the United 
States, France, Italy, Israel, Japan, Nether-
lands, United Kingdom and Sweden), in 
which case it is only necessary to present 
the certificate of approval from those coun-
tries to the regulatory agency. In the second 
case, if the drug has not been previously 
commercialized in Argentina or in the high-
level surveillance countries, the maker must 
offer all relevant efficacy and safety data for 
a full evaluation by Argentina’s National 
Administration of Drugs, Food and Medi-
cal Technology [Administración Nacional 
de Medicamentos, Alimentos y Tecnología 
Médica] (ANMAT). 
In practice, this means that for almost 
the entire drug market in Argentina, the eval-
uation of efficacy and safety was carried out 
by another national agency and accepted as 
valid by the Argentine authorities. 
Although no complete agreement or 
international standard exists, a number of 
classification systems have been developed 
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to categorize the value of new drugs. These 
systems primarily seek to permit health pro-
fessionals and the public access to informa-
tion regarding the therapeutic value added 
by the new drugs in relation to the previ-
ously available options.(9,10,11,12)
A study that evaluated whether or not 
the drugs commercialized in the USA were 
registered, commercialized and sold at ac-
cessible prices in the Latin American coun-
tries where they were tested found great 
price variation among them, with Argentina 
being the country where the absolute prices 
were highest for the drugs evaluated.(13)
The objective of this study is to evalu-
ate the therapeutic value of the new drugs 
approved by ANMAT during the year 2016 
and estimate the monthly cost of treatment.
METHODS
We identified the drugs approved by AN-
MAT for commercialization in Argentina 
during the year 2016, consulting the new 
medicines approved for use with or with-
out prescription published monthly on AN-
MAT’s website.(14)  When a single active 
ingredient had two dosage forms, they were 
analyzed separately. The following products 
were excluded from the study: drugs used for 
diagnosis, including radiological contrasts; 
hydroelectrolitic, nutritional and irrigation 
solutions; products related to hemodialysis; 
and vaccines and immunoglobulins.
According to the composition, each med-
icine was classified as a monodrug or a fixed-
dose combination drug. The corresponding 
World Health Organization’s Anatomical 
Therapeutic Chemical (ATC) code was as-
signed, as indicated in the label authorized 
by ANMAT or utilizing the WHO Collabora-
tive Centre for Drug Statistics Methodology 
database, in accordance with the established 
instructions.(15)
We classified each drug authorized in 
2016 as previously commercialized in Ar-
gentina if there was at least one product 
with the same active ingredients and route 
of administration in the commercial phar-
maceutical catalog in January 2016,(16) and 
as a new drug (ND) in the remaining cases. 
These NDs correspond to new active ingre-
dients, new combinations of active ingredi-
ents, or a new route of administration for an 
already existing active ingredient. The dif-
ferent packaging of drugs with the same ac-
tive ingredients and routes of administration 
were considered to be a single ND in this 
analysis. We identified the indications for 
each ND according to the label authorized 
by ANMAT.
To evaluate the therapeutic value of the 
NDs four different approaches were used: 
the approval by other regulatory agencies, 
the demonstration of their efficacy in ran-
domized clinical trials and types of end-
points studied, the rating provided by the 
journal Prescrire and the application of 
the therapeutic value scale developed by 
Ahlqvist-Rastad et al.
It was established whether or not the 
NDs were authorized by the FDA,(17) and the 
date of approval, the priority assigned to the 
drug(18) and the state of the drug as treatment 
for “neglected” or “orphan” diseases were 
noted. A drug review is “priority” for the 
FDA when the preliminary review indicates 
that the drug treats a serious or life-threat-
ening condition and, if approved, would 
be a significant improvement in the safety 
or effectiveness of the treatment, diagnosis, 
or prevention of a serious or life-threatening 
condition compared to available therapies; 
the review is “standard” in all other cases. If 
was also established whether the drug was 
approved by the EMA,(19) which regulates 
the commercialization of new drugs in the 
European Union. When the ND were not 
approved by the FDA nor by the EMA, it was 
established whether they were authorized 
by the other countries included in the De-
cree 150/92(8) or whether the ANMAT had 
performed an independent evaluation.  In 
the latter case, the corresponding ANMAT 
file was consulted to identify the evaluation 
criteria utilized.
In the second phase, randomized clini-
cal trials showing the efficacy of the ND were 
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identified, based on those described in the la-
bels authorized by the FDA and/or ANMAT; 
if none were described, a search was carried 
out in PubMed using the name of the active 
ingredient and the filter for type of article 
set to “randomized controlled trial.” It was 
considered that a ND has demonstrated effi-
cacy in four situations: 1) when at least one 
randomized clinical trial shows efficacy for 
the indication authorized by ANMAT; 2) in 
the combinations of drugs, if at least one ran-
domized clinical trial shows the efficacy of 
the coadministered individual components 
and the bioequivalence of the combination 
is shown; 3) for new formulations of a drug, 
when the efficacy of the previous formula-
tion is demonstrated by randomized clini-
cal trials and the bioequivalence of the new 
formulation is demonstrated; and 4) “drugs 
with obvious efficacy,” defined as those that, 
even without randomized clinical trials for 
efficacy, are considered to have high intrin-
sic value due to their immediate and obvi-
ous benefits in uncontrolled studies.(20) It was 
noted if the efficacy had been demonstrated 
for clinically relevant variables, validated 
surrogate variables – those for which there 
is strong evidence that modification predicts 
a specific clinical benefit – or only for other 
surrogate variables.(21,22,23,24,25)
In the third phase, the classification 
assigned to the new drug by the journal 
Prescrire, an independent French publication 
that evaluates the new authorized drugs to rate 
the degree of therapeutic progress, tangible to 
the patient, that a ND contributes for a con-
crete indication, positing the benefit/risk bal-
ance of the drug in relation to other available 
therapeutic alternatives.(10) When the drug 
has a number of indications, the Prescrire rat-
ing may be different for each of them. In such 
cases, the best rating among the indications 
authorized by the ANMAT were used.
Lastly, based on all the information ob-
tained, two of the authors independently ap-
plied the therapeutic value evaluation scale 
developed by Ahlqvist-Rastad et al., that em-
phasized the degree of novelty of the drug 
given the previously available options(9) (Ta-
ble 1). The agreement among the observers 
was evaluated with Cohen’s kappa coeffi-
cient and the discrepancies were resolved by 
consensus. 
As none of the classifications utilized up 
to this point have considered the cost of the 
drugs, this aspect was incorporated utilizing 
the sales price to the public published in the 
commercial drug catalog Kairos at the time 
the drug appeared on the market, and was 
expressed in US dollars according to the ex-
change rate for that date. For medications 
for chronic use, a monthly treatment price 
was estimated using the daily dose defined 
by the WHO Collaborative Centre for Drug 
Table 1. Classification system of Ahlqvist-Rastad et al.
Category Subcategory
A Drugs for conditions with no currently available treatment A1 Substantial benefit to patients
A2 Modest therapeutic effect
B Added therapeutic value: the effect for patients appears to be 
better than the available alternatives
B1 Greater efficacy
B2 Greater safety
B3 More convenient dosage
B4 More convenient route of administration
C Similar therapeutic value C1 First drug in a new class
C2 New drug in an already existing class
D Inferior therapeutic value D1 First drug in a new class
D2 New drug in an already existing class
E Uncertain therapeutic value: evaluation limited to surrogate 
endpoints
Source: Own elaboration based on Ahlqvist-Rastad et al.(9)
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Statistics Methodology.(15) For those cases in 
which a daily dose was not established, the 
dosage recommended in the ANMAT-autho-
rized label was utilized, and if this informa-
tion was lacking, the dosage from the FDA 
label was utilized. For drugs used sporad-
ically, the sales price of one packaged unit 
was recorded. For dantrolene, which is only 
commercialized for hospital use, the average 
number of vials needed per episode of malig-
nant hyperthermia was calculated, according 
to the ANMAT-authorized label. 
RESULTS
Between 01/01/2016 and 12/31/2016, the 
ANMAT authorized 825 drugs, of which 
10% (n=82) correspond to a ND. In 79 
cases the approval was for a new active in-
gredient (or a new combination of active in-
gredients) and in the other three cases, for a 
new administration route for an active ingre-
dient already in the market. 
We excluded from the analysis products 
used for diagnosis (n=2) and an irrigation 
solution (n=1). After counting as a single 
drug the different packaging of new drugs 
(with the same active ingredients and ad-
ministration routes), the list was reduced 
to 45 ND incorporated into the Argentine 
market in 2016. These are presented, along 
with the authorized indications, according 
to the ATC classification order (Table 2). All 
NDs were authorized as prescription drug 
products.
Almost a third of the NDs (31%, n=14) 
were combinations of more than one active 
ingredient. The antineoplastic and immu-
nomodulatory drugs were the therapeutic 
class with the greatest number of new drugs 
(33%, n=15, including five monoclonal an-
tibodies and six tyrosine kinase inhibitors), 
followed by antiinfective drugs (13%, n=6) 
(Figure 1).
Table 2. New drugs authorized in Argentina in 2016 and their indications, organized according to the 
chapters of the Anatomical Therapeutic Chemical (ATC) Classification System of the World Health 
Organization.
New drug Indications authorized by ANMAT ATC code
A) Alimentary tract and metabolism
Choline salicylate + Benzocaine Alleviates inflammation and pain caused by ulcerations, wounds or irritation in the lining of the 
mouth.
A01AD11
Metformin hydrochloride +  Dapagliflozin Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when 
treatment with both dapagliflozin and metformin is appropriate.
A10BD15
Nitisinone Hereditary type 1 tyrosinemia A16AX04
B) Blood and blood-forming organs
Epoprostenol Pulmonary arterial hypertension. Anticoagulation in renal dialysis when heparin cannot be used. B01AC09
Eltrombopag Thrombocytopenia in adults and children over 6 years of age with chronic idiopathic 
thrombocytopenic purpura with insufficient response to corticosteroids, immunoglobulin or 
splenectomy / Thrombocytopenia in patients with chronic hepatitis C to allow treatment using 
interferon /  Severe aplastic anemia that has had an insufficient response to immunosuppressive 
therapy.
B02BX05
C) Cardiovascular system
Ambrisentan Pulmonary hypertension, WHO Functional Class II and III. C02KX02
Riociguat Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension, functional 
class II or III.
C02KX05
Sacubitril + Valsartan Chronic heart failure with reduced ejection fraction. C09DX04
Rosuvastatina + Ezetimibe Primary hypercholesterolemia (heterozygous familial and non-familial). C10BA06
Continued on following page. 
ATC= Anatomical Therapeutic Chemical (Classification System); ANMAT= Administración Nacional de Medicamentos, Alimentos y Tecnología Médica.
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Table 2. Continued.
New drug Indications authorized by ANMAT ATC code
D) Dermatologicals
Concentrate of proteolytic enzymes 
enriched in bromelain
Removal of eschar in adults with deep partial- and full-thickness burns. D03BA03
Aciclovir + Hydrocortisone Recurrent oral herpes. D06BB53
Hydroquinone Gradual bleaching of hyperpigmented skin. D11AX11
G) Urologicals
Hyaluronicacid (intravesical use) Treatment of symptoms of interstitial cystitis, cystitis caused by recurrent infections, urolithiasis, 
urinary retention, neoplasia and cystitis induced by radiation.
G04BX
H) Systemic hormonal preparations, excluding sex hormones
Carbetocin Restoration of uterine tone and prevention of postpartum hemorrhage after an elective Cesarean 
section with spinal or epidural anesthesia.
H01BB03
J) General antiinfectives for systemic use
Posaconazole (tablet, delayed release) Prevention of invasive fungal infections cause by Aspergillus and Candida in immunocompromised 
patients. Treatment for infections by Aspergillus that do not improve with amphotericin B or 
itraconazole, or when these drugs must be suspended.
J02AC04
Posaconazole (parenteral) Treatment of infections by Aspergillus, Fusarium, chromoblastomycosis, mycetoma, Coccidiodes, 
that have not responded to other treatments. Also for the prevention of mycosis in high-risk patients 
(acute myeloid leukemia, myelodysplastic syndrome, autologous bone marrow transplantation).
J02AC04
Emtricitabine +Tenofovir disoproxil 
fumarate + Rilpivirine
Complete regimen for the treatment of HIV-1 in adult patients without history of antiretroviral 
treatment and with HIV-1 RNA less than 100,000 copies/ml at the start of treatment and in certain 
adult patients with viral load suppression defined as RNA less than 50 copies/ml and a stable 
antiretroviral regimen at the start of treatment, to replace the current antiretroviral treatment.
J05AR08
Abacavir + Lamivudine + Dolutegravir Adults and children over 12 years of age with HIV who weigh at least 40 kg. Before initiating treatment 
with drugs that contain abacavir, a detection for the allele HLA-B*5701 in all patients infected with 
HIV should be carried out, independent of race. Abacavir should not be used in patients with the gene 
variation HLA-B*5701.
J05AR13
Atazanavir + Cobicistat HIV-1 in adults. J05AR15
Ombitasvir + Paritaprevir + Ritonavir + 
Dasabuvir
Hepatitis C genotype 1, including those with compensated cirrhosis J05AX66
L) Antineoplastic and immunmodulating agents
Brentuximab vedotin Relapsed or refractory Hodgkin’s lymphoma / Relapsed or refractory systemic anaplastic large cell 
lymphoma.
L01XC12
Obinutuzumab In combination with chlorambucil, for the treatment of adult patients with chronic lymphocytic 
leukemia that has not been previously treated, and with comorbidities for which the treatment with 
the full dosage of fludarabine is not appropriate.
L01XC15
Nivolumab Unresectable and metastatic melanoma / Non-small cell lung cancer / Renal cell cancer / Hodgkin’s 
lymphoma.
L01XC17
Pembrolizumab Unresectable and metastatic melanoma. L01XC18
Lapatinib HER2 (ErbB2) overexpressed breast cancer: in combination with capecitabine for advanced 
or metastatic disease that has progressed after receiving previous treatment that includes 
anthracyclines and taxanes, and treatment with trastuzumab in metastatic disease / In combination 
with trastuzumab in patients with metastatic disease and negative hormone receptors that 
have progressed to previous therapies with trastuzumab in combination with chemotherapy / In 
combination with an aromatase inhibitor in postmenopausal women with metastatic disease and 
positive hormone receptors, for whom chemotherapy is not appropriate.
L01XE07
Trametinib Melanoma with BRAF gene mutation, patients that have not received a BRAF inhibitor. L01XE25
Ibrutinib Mantle cell lymphoma / chronic lymphocytic leukemia / chronic lymphocytic leukemia with 
chromosome 17p deletion.
L01XE27
Nintedanib Idiopathic pulmonary fibrosis. L01XE31
Palbociclib Advanced ER(+)/HER2(-) breast cancer post-menopause, associated with letrozole, as initial 
endocrine therapy for metastatic disease.
L01XE33
Olaparib Monotherapy maintenance for relapsed high-grade serous ovarian cancer with BRCA mutation and 
platinum sensitivity in patients that are responding to platinum-based therapy
L01XX46
Continued on following page. 
Source: Own elaboration based on the indications approved by ANMAT. 
ATC= Anatomical Therapeutic Chemical (Classification System); ANMAT= Administración Nacional de Medicamentos, Alimentos y Tecnología Médica.
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Table 2. Continued.
New drug Indications authorized by ANMAT ATC code
Venetoclax Chronic lymphocytic leukemia with chromosome 17p deletion, patients that have received at least 
one prior therapy.
L01XX52
Mifamurtide High-grade resectable non-metastatic osteosarcoma after a macroscopic complete surgical 
resection in children, adolescents and young adults.
L03AX15
Teriflunomide Relapsing-remitting multiple sclerosis. L04AA31
Ustekinumab Moderate to severe plaque psoriasis / Active psoriatic arthritis. L04AC05
Pomalidomide Associated with dexamethasone, in adults with resistant or recurrent multiple myeloma, that have 
received at least two previous treatments, including lenalinomide and bortezomib, and that have 
experienced a progression in the disease in the last treatment.
L04AX06
M) Musculo-skeletal system
Dantrolene sodium 3-1/2  hydrate Malignant hyperthermia M03CA01
Hyaluronic acid sodium salt + lidocaine 
hydrochloride
Symptomatic treatment of pain and articular function in knee arthrosis, shoulder periarthritis and 
other synovial joints.
M09AX01
N) Nervous system
Doxepin Primary insomnia, short-term treatment. N06AA12
R) Respiratory system
Olodaterol Long-term maintenance treatment with daily administration in patients with Chronic Obstructive 
Pulmonary Disease (COPD).
R03AC19
Umeclidinium + Vilanterol Bronchodilator maintenance treatment to alleviate COPD symptoms in adult patients. R03AL03
Olodaterol + Tiotropium bromide Long-term maintenance treatment with daily administration in patients with COPD. R03AL06
Umeclidinium bromide Bronchodilator maintenance treatment to alleviate COPD symptoms in adult patients. R03BB07
S) Sensory organs
Brimonidine + Brinzolamide Open angle glaucoma or ocular hypertension in patients for which monotherapy produces an 
insufficient reduction in intraocular pressure.
S01EC54
V) Various
Citrulline malate Asthenia, once it has been ruled out as a secondary effect of an underlying disease, of any origin 
(physical or psychiatric).
V06DD
Radium 223 dichloride Alpha particle-emitting radioactive therapeutic agent indicated for treatment of patients with 
prostate cancer that is resistant to castration with symptomatic metastasis to the bone and without 
known visceral metastatic disease.
V10XX03
Source: Own elaboration based on the indications approved by ANMAT. 
ATC= Anatomical Therapeutic Chemical (Classification System); ANMAT= Administración Nacional de Medicamentos, Alimentos y Tecnología Médica.
Approval by other regulatory agencies
The majority of the NDs approved by ANMAT 
in 2016 had been previously authorized by 
the FDA (80%, n=36) and the EMA (78%, 
n=35). Of the six ND that were not authori-
zed by either of these two agencies, four had 
approval in countries listed in the Annex I of 
Decree 150/92 (carbetocin, hydroquinone, ro-
suvastatin + ezetimibe, and citrulline malate) 
and the remaining two were evaluated directly 
by ANMAT (hyaluronic acid + lidocaine for 
intra-joint use and choline salicylate + ben-
zocaine as a topical oral treatment). Of the 
36 NDs approved by the FDA, 53% (n=19) 
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qualified for priority review and 42% (n=15) 
were for orphan diseases.
Drugs evaluated directly by ANMAT
The criteria identified in the two original 
evaluations carried out by ANMAT were di-
verse. In the case of choline salicylate and 
benzocaine for topical oral treatment, the 
approval was based on the efficacy and sa-
fety of the individual components, without 
reference to studies that evaluated the fixed-
dose combination.(26) Regarding hyaluronic 
acid and lidocaine for intra-joint use, it was 
framed as a new use of the previously ap-
proved hyaluronic acid, and not as a new 
drug.(27)
Proven efficacy in randomized 
controlled trials
For 62% of the ND (n=28), randomized 
controlled trials were found that demonstra-
ted efficacy; another 20% (n=9) were new 
combinations or formulations of drugs that al-
ready had randomized clinical trials showing 
efficacy, in which case the bioequivalency 
was all that was demonstrated in order for the 
new preparation to be approved (Table 3).
Of the 18% of ND (n=8) without ran-
domized clinical trials for efficacy, 4% (n=2) 
can be categorized as drugs “with obvious 
efficacy,” that is, dantrolene for malignant 
hyperthermia and nitisinone in hereditary ty-
rosinemia. The remaining 13% (n=6) did not 
have randomized clinical trials for efficacy; 
two of these, antineoplastic drugs, were eval-
uated in uncontrolled trials. 
The second aspect to be evaluated was 
whether there was proven efficacy for clinically 
relevant endpoints or for surrogate endpoints 
(validated or not validated). Of the NDs, 44% 
(n=20) showed efficacy in relevant endpoints; 
another 22% (n=10) were effective in vali-
dated surrogate variables: forced expiratory 
volume in the first second (FEV1) for Chronic 
Obstructive Pulmonary Disease (EPOC), (28,29) 
undetectable viral load in HIV drugs,(22) sus-
tained virologic response for hepatitis C, (30,31) 
reduction in low-density lipoproteins (LDL) 
Antineoplastics  / 
Immunmodulators (33%)
Antiinfectives (13%)
Cardiovascular system (9%)
Respiratory system (9%)
Dermatologicals (7%)
Alimentary tract and 
metabolism (7%)
Blood and blood-forming organs (5%)
Musculo-skeletal system (5%)
Various (4%)
Systemic hormones, excluding sex  
hormones and insulin (2%)
Sensory organs (2%) 
Nervous system (2%)
Urologicals (2%)
Figure 1. New drugs (n=45) approved in Argentina in 2016, according to the Anatomical 
Therapeutic Chemical (ATC) classification of the World Health Organization.
Source: Own elaboration based on the Anatomical Therapeutic Chemical (ATC) classification system.(15)
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Table 3. Evaluation of new drugs authorized in Argentina in 2016, according to existence of randomized 
clinical trials for efficacy, type of endpoint with demonstrated benefit, rating assigned by the journal Prescrire 
and the scale created by Ahlqvist-Rastad et al.
ATC code New drug
Randomized 
controlled clinical 
trials for efficacy
Type of endpoint 
with demonstrated 
benefit
Prescrire Rating Scale of Ahlqvist-Rastad et al.
A) Alimentary tract and metabolism
A01AD11 Choline salicylate + Benzocaine No None Not acceptable E
A10BD15 Metformin hydrochloride +  Dapagliflozin Yes-FDC Surrogate-NV Not acceptable D2
A16AX04 Nitisinone Obvious efficacy Relevant Bravo A1
B) Blood and blood-forming organs
B01AC09 Epoprostenol Yes Relevant Offers an advantage C1
B02BX05 Eltrombopag Yes Relevant Nothing new C1
C) Cardiovascular system
C02KX02 Ambrisentan Yes Surrogate-NV Nothing new C2
C02KX05 Riociguat Yes Surrogate-NV Possibly helpful C2
C09DX04 Sacubitril + Valsartan Yes Relevant Possibly helpful B1
C10BA06 Rosuvastatin + Ezetimibe Yes-FDC Surrogate-V Not evaluated C2
D) Dermatologicals
D03BA03 Concentrate of proteolytic enzymes enriched in bromelain Yes Relevant Not evaluated B1
D06BB53 Aciclovir + Hydrocortisone Yes Relevant Not acceptable C2
D11AX11 Hydroquinone Yes Relevant Not acceptable D2
G) Urologicals
G04BX Hyaluronic acid (intravesical use) No No Not evaluated E
H) Systemic hormonal preparations, excluding sex hormones
H01BB03 Carbetocin Yes Relevant Nothing new C2
J) Antiinfectives for systemic use
J02AC04 Posaconazole (tablet, delayed release) Yes-NF Relevant Possibly helpful C2
J02AC04 Posaconazole (parenteral) Yes-NF Relevant Possibly helpful B4
J05AR08 Emtricitabine +Tenofovir disoproxil fumarate + Rilpivirine Yes-FDC Surrogate-V Nothing new C2
J05AR13 Abacavir + Lamivudine + Dolutegravir Yes-FDC Surrogate-V Nothing new C2
J05AR15 Atazanavir + Cobicistat Yes-FDC Surrogate-V Nothing new C2
J05AX66 Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir Yes-FDC Surrogate-V Nothing new C2
L) Antineoplastic and immunmodulating agents
L01XC12 Brentuximab vedotin Yes Relevant Judgment reserved C1
L01XC15 Obinutuzumab Yes Relevant Nothing new C2
L01XC17 Nivolumab Yes Relevant A real advance B1
L01XC18 Pembrolizumab Yes Relevant Nothing new C2
L01XE07 Lapatinib Yes Surrogate-NV Possibly helpful C1
Continued on following page. 
Source: Own elaboration based on information from the evaluations of the journal Prescrire.(10) 
ATC= Anatomical Therapeutic Chemical (Classification System); FDC= fixed-dose combination; NF= new formulation; NV= not validated; V= validated. 
Note: See Methods section for details regarding the categories utilized and the assignment criteria.
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in hyperlipidemia,(22) and intraocular pressure 
in glaucoma treatment.(23) Among the autho-
rized NDs, 24% (n=11) showed efficacy only 
in non-validated surrogate variables and 9% 
(n=4) had no proof of efficacy. These results 
are described in Table 3 and summarized in 
Table 4.
Classification assigned by the journal 
Prescrire
Of the 45 ND authorized in 2016, 39 were 
evaluated in the journal Prescrire. More than 
70% of these did not offer advantages: the 
category encompassing the greatest number 
of drugs was “nothing new” (41%, n=16), 
with another 26% (n=10) classified as “not 
Table 3. Continued.
ATC code New drug
Randomized 
controlled clinical 
trials for efficacy
Type of endpoint 
with demonstrated 
benefit
Prescrire Rating Scale of Ahlqvist-Rastad et al.
L01XE25 Trametinib Yes Relevant Offers an advantage B1
L01XE27 Ibrutinib Yes Relevant Judgment reserved B1
L01XE31 Nintedanib Yes Surrogate-NV Not acceptable E
L01XE33 Palbociclib Yes Surrogate-NV Not acceptable E
L01XX46 Olaparib No-Last line Surrogate-NV Not acceptable E
L01XX52 Venetoclax No-Last line Surrogate-NV Not evaluated C1
L03AX15 Mifamurtide Yes Surrogate-NV Inaceptable E
L04AA31 Teriflunomide Yes Surrogate-NV Inaceptable D2
L04AC05 Ustekinumab Yes Relevant Nothing new C2
L04AX06 Pomalidomide Yes Relevant Possibly helpful B1
M) Musculo-skeletal system
M03CA01 Dantrolene sodium 3-1/2  hydrate Obvious efficacy Relevant Drug of choice* A1
M09AX01 Hyaluronic acid sodium salt + lidocaine hydrochloride No No Not acceptable E
N) Nervous system
N06AA12 Doxepin Yes Surrogate-NV Not evaluated D2
R) Respiratory system
R03AC19 Olodaterol Yes Surrogate-V Nothing new C2
R03AL03 Umeclidinium + Vilanterol Yes Surrogate-V Nothing new C2
R03AL06 Olodaterol + Tiotropium bromide Yes Surrogate-V Nothing new C2
R03BB07 Umeclidinium bromide Yes Surrogate-V Nothing new C2
S) Sensory organs
S01EC54 Brimonidine + Brinzolamide Yes-FDC Surrogate-V Nothing new C2
V) Various
V06DD Citrulline malate No No Nothing new E
V10XX03 Radium 223 dichloride Yes Relevant Nothing new B1
Source: Own elaboration based on information from the evaluations of the journal Prescrire.(10) 
ATC= Anatomical Therapeutic Chemical (Classification System); FDC= fixed-dose combination; NF= new formulation; NV= not validated; V= validated. 
Note: See Methods section for details regarding the categories utilized and the assignment criteria. 
*Although not classified in Prescrire’s progressive therapeutic scale, the journal considers it to be a drug of choice for malignant hyperthermia.
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acceptable” and 5% (n=2) as “judgment reser-
ved.” Only 28% of the ND evaluated by Pres-
crire (n=11) were classified in categories that 
represent a minimum advance with respect to 
the previous therapeutic options (Table 5).
Evaluation of therapeutic value
There was good interobserver agreement 
in assigning therapeutic value to the NDs 
(κ=0,90). The evaluation, according to the 
scale of Ahlqvist-Rastadet al., shows that the 
majority of the ND (51%, n=23) do not have 
added therapeutic value (category C), another 
9% (n=4) are considered inferior to the exis-
ting alternatives (category D) and 18% (n=8) 
have uncertain therapeutic value (E). Only 
22% (n=10) of the ND represent some de-
gree of added therapeutic value (categories A 
and B) (Figure 2 and Table 3).
Table 4. Existence of randomized clinical trials and types of endpoints 
evaluated for the new drugs approved in Argentina in 2016.
Are there RCT showing efficacy? Proof of efficacy No proof of 
efficacy
Total
In relevant 
endpoints
In surrogate endpoints
Validated Not validated
Yes 16  4 8  - 28
Yes – Fixed-dose combination  - 6 1  - 7
Yes – New formulation 2  -  -  - 2
Drugs with obvious efficacy 2  -  -  - 2
No – Last-line oncological drugs  -  - 2  - 2
No  -  -  - 4 4
Total 20 10 11 4 45
Source: Own elaboration. 
RCT=Randomized clinical trials. 
Note: See detailed description of the categories in the Methods section.
Table 5. Evaluation of the journal Prescrire regarding the new drugs (n=39) 
approved in Argentina in 2016.
Category Concept Quantity %
Bravo A major therapeutic advance in an area where previously no 
treatment was available
1 2.6
Of choicea 1 2.6
A real advance An important therapeutic advance but has certain limitations 1 2.6
Offers an advantage The product has some value but does not fundamentally change 
the present therapeutic practice
2 5.1
Possibly helpful The product has minimal additional value, and should not change 
prescribing habits except in rare circumstances
6 15.4
Nothing new The product is a new substance but with no evidence that it has 
more clinical value that other substances of the same group
16 41.0
Not acceptable Product without evident benefit but with potential or real 
disadvantages
10 25.6
Judgment reserved Rating is postponed until better data and a more thorough 
evaluation of the drug are available
2 5.1
Source: Own elaboration using the categories assigned by the journal Prescrire to the new drugs, according to the journal’s 
evaluation system.(10) 
aThis category was used for dantrolene in the treatment of malignant hyperthermia, which was not classified in the 
progressive therapeutic scale of the journal Prescrire, but the journal considers it a drug of choice for this indication.
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Sale price to the public of the new 
drugs
Of the 45 NDs authorized, there were five 
for sporadic use and 40 for chronic use. In 20 
of the chronic use drugs, the monthly price 
of the defined daily dose was calculated; in 
another 17 the dose from the ANMAT label 
was used, and in one the dose from the FDA 
label was used. There were two products (hy-
droquinone and nitisinone) for which it was 
not possible to obtain the sales price.
The treatment price of the new drugs 
for chronic use shows great dispersion, from 
$13 to $56,516 per month (in US dollars). 
The price of most drugs was elevated, with 
an average price of $7,974 and a median 
of $5,849 (interquartile range: Q1=$172; 
Q3=$14,284). For the NDs with added 
therapeutic value, the price was even more 
elevated, with an average price of $13,800 
(median=$13,821; interquartile range: 
Q1=$5,021; Q3=$13,325).
When grouping the drugs by primary 
indication, their concentration into differ-
ent price ranges according to the pathology 
treated can be observed (Figure 3). It can also 
be observed that the monthly price of treat-
ment for the 14 drugs for oncological use 
goes from $3,000 to $56,000, with an aver-
age of $17,700. To contrast this information, 
only five of these drugs had added therapeu-
tic value, five had similar therapeutic value to 
existing drugs, three had unknown therapeu-
tic value and one was considered inferior to 
existing alternatives.
DISCUSSION
This study found that, in the year 2016, 45 
NDs were incorporated into the Argentine 
market, the majority of which were previously 
approved by the FDA and the EMA. Of these 
NDs, 13% did not have randomized clinical 
trials demonstrating efficacy and 24% had 
demonstrated efficacy only for non-validated 
surrogate variables. In terms of therapeutic 
value, 72% of the NDs did not represent sig-
nificant advances according to the evaluation 
of the journal Prescrire and 78% did not add 
therapeutic value according to the classifica-
tion of Ahlqvist-Rastad et al. For the two drugs 
2
7
1
5
18
9
8
0
2
4
6
8
10
12
14
16
18
20
A1 - No
previous 
treatment
B1 - Better 
efficacy
B4 - More 
convenient
C1 - Similar 
value; new 
class
C2 - Similar 
value; new 
drug
D2 - Inferior 
value; new 
drug
E - Uncertain 
therapeutic 
value
Figure 2. Therapeutic value of the new drugs(n=45) approved in Argentina in 2016, 
according to the classification of Ahlqvist-Rastad et al.
Source: Own elaboration based on the classification of therapeutic value by Ahlqvist-Rastad et al.(9)
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evaluated only by ANMAT, the approval crite-
ria used were not robust. In addition, the price 
of the drugs was substantial, with a median of 
$5,849 per month for chronic use drugs. Only 
one out of every 4 NDs represented a thera-
peutic advance and almost all are sold at prac-
tically inaccessible prices.
These results are in agreement with those 
obtained in the previously cited studies. The 
studies carried out in different parts of Latin 
America and the world all show an absence 
of added therapeutic value of the majority of 
the new drugs that are commercialized. In 
synthesis, in the best case scenario, only a 
13
27
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380
506
989
970
2.442
2.512
3.213
5.710
8.294
10.439
9.901
18.274
14.956
27.984
3.007
6.052
6.589
8.306
9.685
12.373
13.821
15.140
16.325
15.389
18.605
21.484
44.685
56.516
$10 $100 $1.000 $10.000 $100.000
Insomnia
Glaucoma
Dyslipidemia
Diabetes
Asthenia
COPD
Heart failure
Arthrosis
HIV-AIDS
Interstitial cystitis
Psoriasis
Thrombocytopenia
Hypertension / Pulmonary fibrosis
Hepatitis C
Invasive mycoces
Oncologicals
(dólares estadounidenses / mes)
Figure 3. Approved new drugs, according to pathology treated and monthly price of 
treatment in US dollars. Argentina, 2016.
Source: Own elaboration using prices published in the catalog Kairos.(16)
Note: The price scale is logarithmic for ease of representation.
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quarter of these drugs represents some type 
of improvement in the existing therapeutic 
options.
The value of these drugs can be ana-
lyzed using two different but complementary 
approaches. The first contemplates the phar-
maceutical innovation and evaluates, for ex-
ample, the novelty of the chemical structure, 
the molecular target, the action mechanism, 
the drug class, the synthesis method or the drug 
formulation.(11,12) The second focus privileges 
the degree to which the new drug represents 
an added therapeutic value with respect to the 
previously available options, that is, its con-
crete additional benefit for patients.(9,10) With 
the first focus, applied by regulatory agencies, 
a drug that is more effective than a placebo 
can be considered innovative, however with 
the second criteria, which is stricter and has 
greater public health relevance, it is necessary 
to demonstrate benefit in clinical trials as com-
pared to the best available alternative.
A number of studies have compared the 
new therapeutic agents registered by the FDA, 
the EMA and other regulatory agencies. Al-
though no significant differences were found 
for the marketed new drugs, a recent study 
observed that the indications approved by the 
FDA, the EMA and the Swiss agency Swiss-
medic (SMC) for the same drugs differed in 
content in 76.9% of cases.(33) It is clear that dis-
crepancies among regulatory agencies are not 
only based on the evidence, but also cultural, 
political and economic factors as well as the 
characteristics of each health care system.(34)
Although the FDA’s designation of dif-
ferent categories such as “priority review” 
or “orphan drug” appears to promote stricter 
innovation criteria, in practice there are so 
many drugs classified as priority that the term 
loses specificity and becomes indiscriminate. 
Regarding the orphan diseases investigated, 
these are usually genetic syndromes or onco-
logical variants with a very low prevalence 
in the USA, and not infectious diseases of 
high prevalence in developing countries, 
for which there are no effective therapeutic 
alternatives.
The therapeutic value of a ND is even 
less certain when, using the “accelerated 
approval” route established by regulatory 
agencies, the drug appears on the market with 
demonstrated efficacy only for non-validated 
surrogate variables or even without controlled 
trials. Examples of these questioned surrogate 
variables include the six-minute walk test for 
pulmonary arterial hypertension(32) and many 
of the habitual endpoints of oncological drug 
studies.(35) The post-commercialization stud-
ies required by regulatory agencies to com-
plete this information exceed the stipulated 
time frame and often do not contribute the 
expected information regarding clinically rel-
evant endpoints.(24,25,36,37,38,39,40)
The result of this lax form of drug ap-
proval is the incorporation of products with 
unproven efficacy and safety in clinically rel-
evant variables, with preliminary safety infor-
mation and, in general, a price that stresses 
the viability of funding mechanisms.
The legal framework in Argentina, which 
permits the inscription of any drug approved 
by the regulatory agencies in developed 
countries,(8) reproduces locally the same 
problems. Bills exist to create an agency for 
the evaluation of health technologies that 
could intervene in the incorporation of new 
drugs into the social security system. It is cru-
cial that in these types of decisions, standards 
be used that consider the added therapeutic 
value of a new drug, in addition to the anal-
ysis of cost-effectiveness in comparison with 
the alternatives. 
However, the results of the analyzed 
studies suggest that to respond to the local 
health priorities larger changes are neces-
sary in the legal framework, abandoning the 
automatic inscription of drugs approved by 
the regulatory agencies of other countries. 
The new form of inscription should include 
an independent evaluation of the new drugs 
and approve the entry into the local market 
of those drugs that represent true advances.
As an example of interventions of this 
type in other Latin American countries, a re-
cent decree in Colombia establishes that the 
inscription of new drugs is dependent on an 
evaluation of their therapeutic value in rela-
tion to a selected comparison, along with an 
economic evaluation, that could include an 
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analysis of cost-effectiveness as well as the 
budget impact.(41) In this way, the evaluation 
of the therapeutic value and the establish-
ment of the price occur prior to the drug en-
tering the local market.
CONCLUSIONS
As a mirror of what occurs in developed 
countries, only a minor fraction of the new 
drugs approved in Argentina in 2016 repre-
sented a significant therapeutic advance. 
Nevertheless, the majority had a very eleva-
ted price. The result is an increase in risks to 
patients who are exposed to drugs without 
proven clinical efficacy and an overburde-
ning of public and private funding systems. 
To improve these results, an evaluation of the 
therapeutic value and the price of the drug 
should be incorporated as a requirement for 
the authorization of the inscription of new 
drugs in Argentina, or at least be a step to 
authorize their inclusion in the social security 
system.
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